EUVIMEDEUVIMED entdecken
Open Access

PSMA PET/CT–derived Tumor Volume for Predicting Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving 177 Lu-PSMA-617

Alireza Ghodsi iD, Lukas Owens iD, Ridvan Arda Demirci iD, Andrei Gafita, Heather H Cheng, Jessica E Hawley iD, Ruben Raychaudhuri, Hiba Khan iD, Rajitha Sunkara, Andrew C Hsieh iD, Petros Grivas iD, Bruce Montgomery und 7 weitere

Radiology · 2026

DOI: 10.1148/radiol.250649 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Radiology, 2026. Verfasst von Alireza Ghodsi und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, University of Washington, Seattle, Wash. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Positron Emission Tomography Computed Tomography, Dipeptides, Heterocyclic Compounds, 1-Ring. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NCI, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Incorporating prostate-specific membrane antigen (PSMA) PET/CT–derived total tumor volume with existing prediction models for overall survival, progression-free survival, and biochemical response to 177 Lu-PSMA-617 improved their discriminatory ability.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantPositron Emission Tomography Computed TomographyDipeptidesHeterocyclic Compounds, 1-RingLutetiumRadioisotopesHumansMaleTumor BurdenAgedRadiopharmaceuticalsPredictive Value of TestsRetrospective StudiesMiddle AgedProstate-Specific AntigenNeoplasm MetastasisTreatment Outcome

Substanzen

DipeptidesHeterocyclic Compounds, 1-RingLutetiumRadiopharmaceuticalsRadioisotopesPSMA-617Prostate-Specific AntigenLutetium-177

Autor:innen und Institutionen

  • Department of Radiology, University of Washington, Seattle, Wash.
  • Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Wash.
  • Department of Radiology, University of Iowa, Iowa City, Iowa.
  • Department of Radiology, Johns Hopkins University, Baltimore, Md.
  • Department of Medicine, University of Washington, Seattle, Wash.
  • Clinical Research Division, Fred Hutchinson Cancer Center, 823 Yale Ave N, Seattle, WA 98109.

ORCID-Profile: Alireza Ghodsi, Lukas Owens, Ridvan Arda Demirci, Jessica E Hawley, Hiba Khan, Andrew C Hsieh, Petros Grivas, Todd A Yezefski, Evan Y Yu, Delphine L Chen, Roman Gulati, Amir Iravani

Förderung

  • NCI NIH HHS
  • NCI
  • National Cancer Institute

Zitieren

APA

Ghodsi, A., Owens, L., Demirci, R. A., Gafita, A., Cheng, H. H., Hawley, J. E., Raychaudhuri, R., Khan, H., Sunkara, R., Hsieh, A. C., Grivas, P., Montgomery, B., Yezefski, T. A., Nelson, P. S., Yu, E. Y., Schweizer, M. T., Chen, D. L., Gulati, R., & Iravani, A. (2026). PSMA PET/CT–derived Tumor Volume for Predicting Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving 177 Lu-PSMA-617. Radiology. https://doi.org/10.1148/radiol.250649

Vancouver

Ghodsi A, Owens L, Demirci RA, Gafita A, Cheng HH, Hawley JE, et al. PSMA PET/CT–derived Tumor Volume for Predicting Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving 177 Lu-PSMA-617. Radiology. 2026. doi:10.1148/radiol.250649

BibTeX
@article{Ghodsi2026,
  author = {Ghodsi, Alireza and Owens, Lukas and Demirci, Ridvan Arda and Gafita, Andrei and Cheng, Heather H and Hawley, Jessica E and Raychaudhuri, Ruben and Khan, Hiba and Sunkara, Rajitha and Hsieh, Andrew C and Grivas, Petros and Montgomery, Bruce and Yezefski, Todd A and Nelson, Peter S and Yu, Evan Y and Schweizer, Michael T and Chen, Delphine L and Gulati, Roman and Iravani, Amir},
  title = {PSMA PET/CT–derived Tumor Volume for Predicting Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving 177 Lu-PSMA-617},
  journal = {Radiology},
  year = {2026},
  doi = {10.1148/radiol.250649}
}
Kostenlos starten →